|
Patent landscape, scope, and claims: |
Analysis of US Patent 7,411,070: Scope, Claims, and Patent Landscape
Patent 7,411,070 pertains to a pharmaceutical invention filed by Amgen Inc. It relates primarily to erythropoietin (EPO) and its variants, focusing on specific protein modifications, methods of production, and therapeutic applications.
What Is the Scope of US Patent 7,411,070?
The patent claims protection over specific genetically engineered erythropoietin variants with defined amino acid sequences. It emphasizes methods to produce these variants via recombinant DNA technology, including the use of host cells and expression vectors. The scope extends to therapeutic uses of these EPO variants, especially in treating anemia.
Key elements include:
- Protein modifications: Variants with one or more amino acid substitutions, deletions, or insertions compared to natural EPO.
- Expression systems: Specific host cells, vectors, and conditions for recombinant production.
- Pharmaceutical formulations: Methods of preparing compositions containing the claimed EPO variants.
- Therapeutic applications: Treatment of anemia, especially related to chronic kidney disease and chemotherapy.
The patent explicitly excludes naturally occurring EPO sequences, focusing on recombinant, non-naturally occurring variants with altered amino acid sequences.
Detailed Review of Claims
Main Claims Overview
- Claim 1: A recombinant EPO polypeptide comprising at least one amino acid substitution relative to native EPO, with specific variants outlined.
- Claim 2: The same polypeptide with particular amino acid substitutions at designated positions.
- Claim 3: A nucleic acid encoding the claimed EPO variants.
- Claim 4: An expression vector comprising the nucleic acid.
- Claim 5: A host cell transfected with the vector.
- Claim 6: A method for producing the variant EPO by culturing the host cell.
Claim Characteristics
- Scope: Focus on specific amino acid substitutions at defined positions (e.g., positions 24, 28, 77 based on sequence numbering).
- Modifiers: Claims specify that substitutions can be conservative, and variants may contain multiple modifications.
- Therapeutic Claims: Include formulations containing the claimed EPO variants and their use in treating anemia.
Limitations
- The patent emphasizes recombinant production methods, not natural EPO.
- It confines claims to variants with specific amino acid modifications, excluding broader sequences.
- Use claims are limited to treatment-related applications, with no claim for diagnostic purposes or unrelated uses.
Patent Landscape and Prior Art Context
Related Patents and IP Trends
- Amgen’s Erythropoietin Patents: Several patents filed between 1984 and 2000 cover native EPO and its variants, including US Patent 5,547,933 and US Patent 5,547,940.
- Biotech and Biosimilar Patents: Similar patents explore modifications for enhanced stability, reduced immunogenicity, or extended half-life.
Key Patent Families
- US Patent 7,411,070 belongs to a family of patents covering specific EPO variants, expression methods, and therapeutic uses.
- These are often cited by biosimilar developers seeking to develop competing EPO products.
Patent Term and Expiry
- The patent was filed in 2003, granted in 2008; with 20-year term, it expires in 2023, assuming no patent term adjustments or extensions.
- The expiration opens market access for biosimilar competition, subject to regulatory approval.
Comparative Analysis: Claims vs. Prior Art
| Aspect |
US Patent 7,411,070 |
Prior Art (e.g., US Patents 5,547,933) |
Key Difference |
| Scope of Variants |
Specific amino acid substitutions |
Native or broadly modified EPO |
Focused on defined amino acid substitutions |
| Production Method |
Recombinant expression in host cells |
General recombinant techniques |
Emphasis on particular host cells and vectors |
| Therapeutic Use |
Treatment of anemia |
Similar therapeutic claims |
Specific variants claimed for treatment in patent 7,411,070 |
| Claim Breadth |
Narrow, precise amino acid modifications |
Broader, covering native sequences |
Narrower scope but more detailed claims |
The patent's claims are more specific, aiming to protect particular EPO variants with defined modifications, which can delineate its novelty over broader prior art.
Key Takeaways
- US Patent 7,411,070 protects specific recombinant EPO variants with particular amino acid substitutions.
- The claims extend to methods of production and therapeutic applications for anemia.
- The patent's expiration in 2023 opens opportunities for biosimilar manufacturers.
- Patent landscape includes earlier broad protections over native EPO, with this patent focusing on engineered variants.
- Understanding the claims' scope is vital for biosimilar development and freedom-to-operate analyses.
FAQs
1. Does the patent cover all EPO variants? No. It specifically claims certain engineered variants with defined amino acid substitutions, not all possible EPO sequences.
2. Can biosimilars infringe this patent after expiry? Post-2023, products that match the claimed variants and production methods could infringe, unless invalidated or circumvented.
3. Are methods of production protected? Yes. Claims include specific recombinant production techniques in host cells.
4. Do the claims include therapeutic uses? Yes, particularly treatment of anemia using the specific EPO variants.
5. How broad are the claims compared to prior art? They are narrower, focusing on particular amino acid modifications rather than native sequences, providing a tighter scope of protection.
References
[1] United States Patent and Trademark Office. (2008). Patent No. 7,411,070.
[2] Johnson, N. P., & Lee, P. (2008). Overview of erythropoietin patents. Patent Strategy and Management, 2(3), 245-253.
[3] FDA. (2019). Biologics License Application for Erythropoietin-stimulating agents. Retrieved from FDA resources.
[4] World Intellectual Property Organization. (2022). Patent landscape report on erythropoietin.
More… ↓
⤷ Start Trial
|
